ArticleEuropean journal of nuclear medicine and molecular imaging2021
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03980431 (Safety and Clinical Value of 18Fluorine-labeled Boron Tyrosine PET/CT in Patients With Brain Tumors), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Clinical Value of 18Fluorine-labeled Boron Tyrosine PET/CT in Patients With Brain Tumors
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Detailed pharmacokinetic features of a novel bis-boronEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Core clinical procedures and efficacy-enhancing strategies in boron neutron capture therapy.Discover oncology · 2026Review
- CD98 Light Chain LAT1 Tracers in PET-CT Diagnosis of Cancer Patients.Anti-cancer agents in medicinal chemistry · 2026Review
- PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington's disease.European journal of nuclear medicine and molecular imaging · 2025Article
- LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals.Theranostics · 2025Review
- A bis-boron boramino acid PET tracer for brain tumor diagnosis.European journal of nuclear medicine and molecular imaging · 2024Article
- A histogram of [EJNMMI research · 2024Article
- A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China.Cancers · 2023Review
- Recent Development of Radiofluorination of Boron Agents for Boron Neutron Capture Therapy of Tumor: Creation ofPharmaceuticals (Basel, Switzerland) · 2023Review
- Radiopharmaceuticals heat anti-tumor immunity.Theranostics · 2023Review
- The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning.Theranostics · 2023Review
- Carborane-Containing Folic AcidInternational journal of molecular sciences · 2022Article
- Recent Advances inPharmaceutics · 2022Review
- LargerEJNMMI research · 2022Article
- First-in-human study of anEuropean journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this work, the safety, biodistribution, and radiation dosimetry of large neutral amino acid transporter type-1 (LAT-1) targeting PET tracer
methodsSix healthy volunteers (3 M, 3 F) underwent whole-body PET acquisitions at multiple time points after bolus injection of
results
conclusion
trial registrationclinicaltrials.gov (NCT03980431).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.